newsfilter
← Latest News
Business Wire·

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

GH

This milestone underscores the power of Guardant Health's InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations Guardant Health, Inc. (NASDAQ:GH), a